Beijing Science Sun Pharmaceutical Co., Ltd. (SHE:300485)

SHE:300485 Revenue

Beijing Science Sun Pharmaceutical had revenue of 81.75M CNY in the quarter ending September 30, 2026, a decrease of -26.89%. This brings the company's total for the last twelve months to 358.57M, down -10.85% year-over-year. In the year 2025, Beijing Science Sun Pharmaceutical had annual revenue of 404.72M, down -2.82%. That makes Beijing Science Sun Pharmaceutical the 27,459th largest company in the world by revenue and 4,760th in China.

• Revenue (ttm): 358.57M
• Revenue Growth: -10.85%
• P/S Ratio: 9.99
• Revenue / Employee: 733.27K
• Employees: 489
• Market Cap: 3.58B

Revenue Chart

Chart

Chart

Revenue by Segment

By Segment

Chart

• Medicine Manufacturing 398.32M 98.4%
• Unallocated Other Operations 6.40M 1.6%

By Geography

Chart

• East China 116.55M 28.8%
• Northeast China 69.20M 17.1%
• Central China 61.51M 15.2%
• Northern China 57.62M 14.2%
• Southwest China 55.19M 13.6%
• South China 36.34M 9.0%
• Northwestern China 8.30M 2.1%

Fiscal year ended Dec 31, 2025 See the full SHE:300485 breakdown

Revenue History

Fiscal Year End	Revenue	Change	Growth
Dec 31, 2025	404.72M	-11.76M	-2.82%
Dec 31, 2024	416.48M	-60.09M	-12.61%
Dec 31, 2023	476.57M	-257.98M	-35.12%
Jan 1, 2023	734.55M	-316.26M	-30.10%
Jan 1, 2022	1.05B	-43.42M	-3.97%

Data Source: S&P Global Market Intelligence Last updated: Oct 28, 2026

Revenue data is provided by S&P Global Market Intelligence and updates within hours after each earnings release, which is every three months for this company.

Update frequency:

Quarterly

Last checked:

Nov 9, 2026

Data Sources Report a data error